4D Molecular Therapeutics

Company snapshot

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of

• 19 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 US patent(s) indexed to this assignee profile.
• 19 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for 4D Molecular Therapeutics. Not investment advice.

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for 4D Molecular Therapeutics.

1. Jun 8, 2026 Clinical update

   4D-150-C004 — Phase 3

2. Jun 8, 2026 Clinical update

   MRx0518 Capsules — Phase 1

3. Jun 8, 2026 Clinical update

   MRx-4DP0004 — Phase 2

4. Jun 8, 2026 Clinical update

   4D-150 IVT — Phase 2

5. Jun 8, 2026 Clinical update

   4D-150 IVT (3E10 vg/eye) — Phase 3

View all clinical trial activity →

• What is 4D Molecular Therapeutics?

  4D Molecular Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker FDMT. Primary therapeutic focus areas include Choroideremia, X-Linked Retinitis Pigmentosa, Macular neovascularization secondary to age-related macular degeneratio

• Is 4D Molecular Therapeutics publicly traded?

  Yes. 4D Molecular Therapeutics is listed with ticker FDMT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does 4D Molecular Therapeutics develop or market?

  We link 13 drug profile(s) where 4D Molecular Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/4d-molecular-therapeutics#company-drugs.

• What are the latest developments for 4D Molecular Therapeutics?

  In the last 12 months our linked public records show 19 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does 4D Molecular Therapeutics focus on?

  4D Molecular Therapeutics focuses on Choroideremia, X-Linked Retinitis Pigmentosa, Macular neovascularization secondary to age-related macular degeneration (nAMD) based on our analysis of their pipeline programs and drug development activities.